Anti-Mouse CD134 (OX-86)

CD134 Monoclonal Antibody for FC

Host / Isotype

Rat / IgG1, kappa

Reactivity

Mouse

Applications

FC

Conjugate

Unconjugated

CloneNo.

OX-86

Cat no : 65136-1-Ig

Synonyms

ACT35, CD134, Ly 70, Ox40, Tnfrsf4, Txgp1, TXGP1L

---

Validation Data Gallery

• 

  FC experiment of BALB/c mouse splenocytes using 65136-1-Ig

  1X10^6 Con-A stimulated BALB/c mouse splenocytes were surface stained with CoraLite® Plus 647 Anti-Mouse CD3 (CL647-65077, Clone: 17A2), 1 ug Anti-Mouse CD134 (65136-1-Ig, Clone: OX-86) or rat IgG1 isotype control, and FITC anti-rat IgG1 Antibody at dilution 1:100. Cells were not fixed.

---

Tested Applications

• Positive FC detected in: Con-A stimulated mouse splenocytes

Recommended dilution

Application	Dilution
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

65136-1-Ig targets CD134 in FC applications and shows reactivity with Mouse samples.

• Tested Reactivity: Mouse
• Host / Isotype: Rat / IgG1, kappa
• Class: Monoclonal
• Type: Antibody
• Immunogen: N/A
• Full Name: tumor necrosis factor receptor superfamily, member 4
• GenBank Accession Number: BC065782
• Gene Symbol: Tnfrsf4
• Gene ID (NCBI): 22163
• RRID: AB_2918423
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Affinity purification
• Storage Buffer: PBS with 0.09% sodium azide.
• Storage Conditions: Store at 2-8°C. Stable for one year after shipment.

Background Information

CD134, also known as OX40 and TNFRSF4, is a member of the TNFR-superfamily of receptors (PMID: 2828930; 9766631). It is a type I transmembrane protein predominantly expressed on activated T cells which include CD4 and CD8 T cells, Th2, Th1, and Th17 cells, as well as regulatory T cells (Tregs) (PMID: 20307208). CD134 is activated by its cognate ligand CD134L (OX40L) and functions as a T cell co-stimulatory molecule (PMID: 26215166). CD134-CD134L interactions have been proposed as a potential therapeutic target for treating autoimmune diseases, cancer and infectious disease (PMID: 26215166; 19426222).